Pharmacokinetic study reveals breastmilk concentrations of sofosbuvir and velpatasvir in women with opioid use disorder, indicating safety for infants.
In this breastmilk pharmacokinetic study of women undergoing hepatitis C virus treatment with sofosbuvir/velpatasvir, sofosbuvir, GS-331007 (sofosbuvir metabolite), and velpatasvir concentrations in breast milk were 13%, 1.2%, and 41% of maternal plasma concentrations, respectively. The estimated infant daily dose from breastmilk was <1% of the weight-adjusted dose for children.
No takes yet. Share an insight, caveat, or question.
Chappell et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: